{"schema_version":"secwatch.filing_event.v1","accession":"0001740797-24-000033","form_type":"8-K","ticker":"AVAI","cik":"0001740797","company_name":"AVAI BIO, INC.","filed_at":"2024-07-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.379398+00:00","generated_at":"2026-05-31T20:43:21.092190+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Avant Technologies appoints Kenneth L. Waggoner as CEO with $720K salary in shares","bullets":["Kenneth L. Waggoner named CEO effective July 10, 2024; 1-year term renewable automatically.","Base salary $720k annual paid in common shares quarterly at 20-day VWAP; increases to $1.44M upon national exchange listing.","Additional bonus of 10% of net equity financing raised if deemed sufficient by Board.","Former interim CEO Hisey reappointed as CFO; Racius reappointed as COO while remaining Director and Treasurer.","CEO has 45 years experience including senior roles at Chevron and PharmaCyte Biotech."],"urls":{"canonical":"https://secwatch.observer/filing/0001740797-24-000033","json":"https://secwatch.observer/filing/0001740797-24-000033.json","markdown":"https://secwatch.observer/filing/0001740797-24-000033.md","text":"https://secwatch.observer/filing/0001740797-24-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740797/000174079724000033/0001740797-24-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740797/000174079724000033/avai_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:43:21.092190+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7cb1bc0b26","claim":"Hisey was appointed as Chief Financial Officer at AVAI BIO, INC..","evidence_excerpt":"Mr. Hisey, the current interim CEO of the Company, was reappointed as Chief Financial Officer (the “CFO”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1740797/000174079724000033/0001740797-24-000033-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"reappointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"f4f22bae20","claim":"Racius was appointed as Chief Operating Officer at AVAI BIO, INC..","evidence_excerpt":"Mr. Racius, the current CFO, Director, and Treasurer, was reappointed as the Company's Chief Operating Officer (the “COO”) while continuing his roles as Director and Treasurer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1740797/000174079724000033/0001740797-24-000033-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"reappointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}